![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
News|Podcasts|June 19, 2021
OncView™ Podcast: Management of Relapsed/Refractory Follicular Lymphoma
Author(s)Matthew Fowler
This special edition of the “Oncology Peer Review On-The-Go” podcast details treatment options and considerations for relapsed/refractory follicular lymphoma.
Advertisement
As part of its OncView™ video series, CancerNetwork® spoke with Sameh Gaballa, MD, of the Moffit Cancer Center, about current and future treatment options and considerations for patients with relapsed/refractory follicular lymphoma (R/R FL).
In the video series, Gaballa discussed the following:
Treatment Options in Relapsed/Refractory Follicular Lymphoma Considerations for Treatment Selection in R/R FL Third-Line Therapy in Follicular Lymphoma Tazemetostat for Relapsed/Refractory Follicular Lymphoma R/R FL: The Role of PI3K Inhibitors Unmet Needs and Looking Ahead in Follicular Lymphoma
To watch more videos in CancerNetwork®’s OncView™ series, visit
Advertisement
Related to this article
Posters highlighted sex-based differences in aggressive B-cell NHL, third-line therapies in aggressive BCL, and real-world safety with CD20/CD3 bispecifics.
Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.
SOHO 2026 sessions covered chemoimmunotherapy in frontline DLBCL, treatment selection via molecular classifiers, and bispecific antibodies for unfit patients.
Jasmine Zain, MD, emphasized the importance of good patient counseling when outlining the potential risks of secondary T-cell malignancies following CAR T-cell therapy.
Adult T-cell lymphoma and leukemia may warrant up-front allogeneic transplant, according to Mary Jo Lechowicz, MD.
The IND clearance for IASO208, a CD20-targeted in vivo CAR-T therapy requiring no leukapheresis or lymphodepletion, enables advancement of a phase 1b trial.
The risk of infections with epcoritamab plus R2 appeared to level off after the first 4 cycles of therapy in the EPCORE FL-1 trial.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
COA Warns That Price Negotiation for Medicare Part B Drugs Threatens Community Oncology
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
Using Intrathecal Dendritic Cells for Leptomeningeal Disease From Breast Cancer
5